SEC Comment Letter for ENZON PHARMACEUTICALS, INC. (ENZN) (CIK 0000727510) (VISK) — Feb 9, 2009

ENZON PHARMACEUTICALS, INC. (ENZN) (CIK 0000727510)
Date: Feb. 9, 2009 · CIK: 0000727510 · Accession: 0000000000-09-006704

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 000-12957

Date

February 6, 2009

Author

Joel Parker

Form

UPLOAD

Company

ENZON PHARMACEUTICALS, INC. (ENZN) (CIK 0000727510)

Letter

Via Facsimile and U.S. Mail Mail Stop 6010 February 6, 2009 Craig A. Tooman Executive Vice President, Finance and Chief Financial Officer Enzon Pharmaceuticals, Inc. 685 Route 202/206 Bridgewater, NJ 08807

Re: Enzon Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2007 Filed February 29, 2008 File Number: 000-12957

Dear Mr. Tooman:

We have completed our review of your Form 10-K and have no further comments at this time. S i n c e r e l y , Joel Parker A c c o u n t i n g B r a n c h C h i e f

Show Raw Text

Via Facsimile and U.S. Mail Mail Stop 6010                                                                                                  February 6, 2009
Craig A. Tooman
Executive Vice President, Finance and
Chief Financial Officer
Enzon Pharmaceuticals, Inc.
685 Route 202/206
Bridgewater, NJ 08807

Re:    Enzon Pharmaceuticals, Inc.
 Form 10-K for the Fiscal Year Ended December 31, 2007
 Filed February 29, 2008
 File Number:  000-12957

Dear Mr. Tooman:

  We have completed our review of  your Form 10-K and have no further
comments at this time.            S i n c e r e l y ,
Joel Parker
        A c c o u n t i n g  B r a n c h  C h i e f

SecProbe.io